Skip to main content

Generic Selzentry Availability

Last updated on Jan 11, 2023.

Selzentry is a brand name of maraviroc, approved by the FDA in the following formulation(s):

SELZENTRY (maraviroc - solution;oral)

  • Manufacturer: VIIV HLTHCARE
    Approval date: November 4, 2016
    Strength(s): 20MG/ML [RLD]

SELZENTRY (maraviroc - tablet;oral)

Has a generic version of Selzentry been approved?

A generic version of Selzentry has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Selzentry and have been approved by the FDA:

maraviroc tablet;oral

  • Manufacturer: HETERO LABS LTD III
    Approval date: February 7, 2022
    Strength(s): 150MG [AB], 300MG [AB]

Note: No generic formulation of the following product is available.

  • maraviroc - solution;oral

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Selzentry. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Tropane derivatives useful in therapy
    Patent 6,667,314
    Issued: December 23, 2003
    Inventor(s): Manoussos; Perros & David Anthony; Price & Blanda Luzia Christa; Stammen & Anthony; Wood
    Assignee(s): Pfizer, Inc.

    The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.

    Patent expiration dates:

    • February 6, 2022
      ✓ 
      Pediatric exclusivity
  • Tropane derivatives useful in therapy
    Patent 7,368,460
    Issued: May 6, 2008
    Inventor(s): Perros; Manoussos & Price; David Anthony & Stammen; Blanda Luzia Christa & Wood; Anthony
    Assignee(s): Pfizer, Inc.

    The present invention provides compounds of the formula: wherein R1 is C3-6 cycloalkyl optionally substituted by one or more fluorine atoms, or C1-6 alkyl optionally substituted by one or more fluorine atoms, or C3-6 cycloalkylmethyl optionally ring-substituted by one or more fluorine atoms; and R2 is phenyl optionally substituted by one or more fluorine atoms, to pharmaceutically acceptable salts and solvates thereof, and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such compounds.

    Patent expiration dates:

    • November 25, 2022
      ✓ 
      Patent use: METHOD OF TREATING PATIENTS INFECTED WITH CCR5-TROPIC HIV-1
    • May 25, 2023
      ✓ 
      Pediatric exclusivity

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • October 30, 2023 - NEW PATIENT POPULATION
    • April 30, 2024 - PEDIATRIC EXCLUSIVITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.